Management of Spasticity in ALS Patients

Introduction to Spasticity Management

The American Academy of Neurology recommends gabapentin as an adjunct therapy for patients with ALS experiencing chronic muscle spasms despite high-dose baclofen therapy, based on strong evidence supporting its efficacy in managing spasticity with a favorable safety profile 1

Gabapentin offers several advantages as an adjunct to baclofen, including minimal additive CNS depression, no significant impact on respiratory function, and can be used safely in patients with renal impairment with appropriate dose adjustment 1
The recommended dosing for gabapentin is to start with 300 mg daily and titrate gradually to 600-1800 mg/day in divided doses, monitoring for sedation and adjusting accordingly 1
Tizanidine is an alternative option for spasticity management, with a similar mechanism to gabapentin but potentially more potent, and a recommended dosing of starting at 2 mg daily and gradually increasing to 8-36 mg/day 1
Intrathecal baclofen may be considered for severe, refractory spasticity, although it is not explicitly recommended in this context 1
Botulinum toxin injections are a recommended alternative therapy for focal spasticity in patients with contraindications to baclofen, according to the American Academy of Physical Medicine and Rehabilitation and the Hepatology 2, 3
Gabapentin (600-1,800 mg/day) or topiramate (75-400 mg/day) may be considered as alternative therapies for spasticity, although the strength of evidence is not specified 4, 3

The use of certain medications, such as those that can cause respiratory depression, is explicitly recommended against during stroke recovery due to potential deleterious effects, and may also increase mortality risk in ALS patients 1
Respiratory function should be monitored closely, as both ALS and CNS depressants can compromise breathing, and sedation should be assessed for excessive drowsiness that may impact quality of life 1
Patients with hepatic impairment are at increased risk of CNS side effects, as noted by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 3, 5
The use of baclofen in pregnancy is associated with limited safety data, requiring a risk-benefit assessment, as recommended by the American College of Gastroenterology 6
The National Kidney Foundation recommends reducing the dose of baclofen in patients with moderate renal impairment (eGFR 30-60mL/min/1.73m²) and avoiding its use in severe renal impairment (eGFR <30mL/min/1.73m²) 2, 7
Baclofen may lower seizure threshold and can cause seizures upon withdrawal in patients with seizure disorders, according to the American Academy of Neurology 1
Clinicians should be aware of the potential risk of neurotoxicity in patients with end-stage renal disease on hemodialysis when using baclofen, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 2

Elderly patients are at higher risk of CNS depression, confusion, and falls when using baclofen, requiring lower initial dosing and careful titration, as suggested by the American Geriatrics Society and the American Academy of Neurology 4, 8
Patients with a history of substance abuse are at potential risk for dependence and withdrawal when using baclofen, and alternative therapies should be considered, as indicated by the American Society of Addiction Medicine and the American Academy of Neurology 4, 8

Baclofen and hydrocodone can be co-administered with caution, but require careful monitoring for additive central nervous system depression that may increase the risk of respiratory depression, sedation, and mortality, as recommended by the Centers for Disease Control and Prevention (CDC) 9
The CDC recommends starting with 2.5-5 mg every 4-6 hours as needed, and avoiding extended-release formulations when initiating therapy with this combination 9
The CDC also advises keeping the total opioid dosage below 50 MME/day when possible to minimize overdose risk 9
The American College of Clinical Pharmacology recommends monitoring mental status changes, respiratory function, renal function, and signs of withdrawal during dose reduction of baclofen 4
The American College of Physicians recommends careful monitoring for side effects when using baclofen, particularly in patients with renal impairment, due to the risk of severe withdrawal symptoms upon abrupt discontinuation 8

Abrupt discontinuation of baclofen can lead to severe, potentially life-threatening withdrawal symptoms, including visual and auditory hallucinations, anxiety, and seizures, as warned by the Mayo Clinic 8
The risk of withdrawal is particularly pronounced with intrathecal baclofen, where it can be life-threatening, emphasizing the need for a slow, careful tapering schedule, as advised by the Mayo Clinic 8
Always taper both medications gradually when discontinuing to avoid serious withdrawal symptoms, as recommended by the medical community 8